« Return to News | Awards & Advancement

X-Change names new president

Wednesday, July 3, 2013 08:52 AM

X-Change, a company specializing in natural cannabinoid-based food and cosmetic products, has appointed former GlaxoSmithKline executive Dr. Dorothy Bray, Ph.D., president. Bray has experience in drug development, including specific expertise in plant-based research in medicine and nutrition.

Bray was global director of HIV Research and senior clinical program head of HIV and opportunistic infections at GSK. Bray also served as senior medical strategy head, international medical affairs and as principal clinical research scientist at antivirals, U.K. and U.S.  She was head of scientific business development of the medical research council clinical trials unit in the U.K.

Bray received a fellowship from the Winston Churchill Memorial Trust in the U.K. to study medicinal plants in Africa, a research grant from the Sir Halley Stewart Trust to study natural products and a fellowship from the Royal Society to study immune system response to natural products. Bray also served as a research fellow at the London School of Hygiene and Tropical Medicine, where she studied the chemical compounds and selected molecules of medicinal plants in collaboration with the World Health Organization (WHO) Tropical Diseases Program and the University of Geneva.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.